Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments
by Zacks Equity Research
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
Merck (MRK) Halts Another Late Stage Study on Alzheimer's
by Zacks Equity Research
Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
Biogen Halts Tysabri Development in Stroke as Study Fails
by Zacks Equity Research
Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat
by Zacks Equity Research
Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.
Biogen (BIIB) Q4 Earnings Miss, Sales Top, Stock Up
by Zacks Equity Research
Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.
What's in the Cards for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips
by Zacks Equity Research
Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.
3 Pharma and Biotech Stocks to Watch Out for in 2018
by Arpita Dutt
Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.
Roche MS Drug Ocrevus Gets Marketing Authorization in Europe
by Zacks Equity Research
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
by Zacks Equity Research
Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer
by Arpita Dutt
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Biogen's Alzheimer's Drug Misses Goal in Interim Analysis
by Zacks Equity Research
Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies
by Zacks Equity Research
Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
by Arpita Dutt
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
by Arpita Dutt
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
by Zacks Equity Research
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal
by Arpita Dutt
While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.
Top Research Reports for Amazon, AbbVie & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), AbbVie (ABBV) and Biogen (BIIB).
Biogen Acquires Worldwide License for Alkermes' MS Candidate
by Zacks Equity Research
Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.
Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil
Should You Buy the Beaten Down Blue-Chip Stocks?
by Tracey Ryniec
Just because a stock plunges to multi-year lows, that doesn't mean it's a value stock.